Evidence map›Paper›PMID 28969431›Full record

Trial reportAIDS research and human retroviruses2018

Intradermal HIV-1 DNA Immunization Using Needle-Free Zetajet Injection Followed by HIV-Modified Vaccinia Virus Ankara Vaccination Is Safe and Immunogenic in Mozambican Young Adults: A Phase I Randomized Controlled Trial.

Edna Omar Viegas, Nelson Tembe, Charlotta Nilsson, Bindiya Meggi, Cremildo Maueia, Orvalho Augusto, Richard Stout, Gabriella Scarlatti, Guido Ferrari, Patricia L Earl and 7 more

Abstract readClinical Trial, Phase IRandomized Controlled Trial
In one paragraph

Trial report in AIDS research and human retroviruses, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 18 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Review
  7. Observational
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 3 countries.

Edna Omar Viegas1 Instituto Nacional de Saúde , Maputo, Mozambique .
Nelson Tembe1 Instituto Nacional de Saúde , Maputo, Mozambique .
Charlotta Nilsson2 Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet , Huddinge, Sweden .
Bindiya Meggi1 Instituto Nacional de Saúde , Maputo, Mozambique .
Cremildo Maueia1 Instituto Nacional de Saúde , Maputo, Mozambique .
Orvalho Augusto3 Eduardo Mondlane University , Maputo, Mozambique .
Richard Stout5 Bioject, Inc. , Tualatin, Oregon.
Gabriella Scarlatti6 IRCCS San Raffaele Scientific Institute , Milan, Italy .
Guido Ferrari7 Department of Surgery and Molecular Genetics and Microbiology, Duke University Medical Center , Durham, North Carolina.
Patricia L Earl8 Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAD)/National Institutes of Health (NIH) , Bethesda, Maryland.
Britta Wahren9 Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet , Stockholm, Sweden .
Sören Andersson10 Department of Laboratory Medicine, Faculty of Medicine and Health, Örebro University , Örebro, Sweden .
Merlin L Robb11 The Military HIV Research Program, Walter Reed Army Institute of Research and The Henry M. Jackson Foundation for the Advancement of Military Medicine , Bethesda, Maryland.
Nafissa Osman3 Eduardo Mondlane University , Maputo, Mozambique .
Gunnel Biberfeld9 Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet , Stockholm, Sweden .
Ilesh Jani1 Instituto Nacional de Saúde , Maputo, Mozambique .
Eric Sandström12 Department of Education and Clinical Research, Karolinska Institutet , Stockholm, Sweden .
Instituto Nacional de Saúde · MZKarolinska Institutet · SEEduardo Mondlane University · MZIstituti di Ricovero e Cura a Carattere Scientifico · ITÖrebro University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We assessed the safety and immunogenicity of HIV-DNA priming using Zetajet™, a needle-free device intradermally followed by intramuscular HIV-MVA boosts, in 24 healthy Mozambicans. Volunteers were randomized to receive three immunizations of 600 μg (n = 10; 2 × 0.1 ml) or 1,200 μg (n = 10; 2 × 0.2 ml) of HIV-DNA (3 mg/ml), followed by two boosts of 10

Indexed as

Immunization ScheduleAdministration, CutaneousAdolescentAdultAIDS VaccinesAntibodies, NeutralizingDouble-Blind MethodDrug-Related Side Effects and Adverse Reactionsenv Gene Products, Human Immunodeficiency VirusEnzyme-Linked Immunospot AssayFemalegag Gene Products, Human Immunodeficiency VirusHIV-1HIV AntibodiesHumansInjections, IntramuscularAIDS VaccinesAntibodies, Neutralizingenv Gene Products, Human Immunodeficiency Virusgag Gene Products, Human Immunodeficiency VirusHIV AntibodiesInterferon-gammaPlacebosVaccines, DNAVaccines, SyntheticHIVHIV-DNAHIV-MVAMozambiquevaccine

Identifiers

PMID28969431
PMCPMC6913121
OpenAlexW2774336495

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.